Trial · NCT02312219
PET/CT Imaging Companion Study To ACTG A5314
NCT02312219, Completed, Massachusetts General Hospital; results first posted 2019-02-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. PET/CT Imaging Companion Study To ACTG A5314. Trials, record NCT02312219. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02312219
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PET/CT Imaging Companion Study To ACTG A5314
- NCT number
- NCT02312219
- Status
- Completed
- Enrollment
- 35 participants, actual
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- HIV, Inflammation, Atherosclerosis
- Interventions
- Folic Acid, Placebo, Low Dose Methotrexate
- First posted
- 2014-12-09
- Last updated
- 2019-02-06
- Results first posted
- 2019-02-06
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Arterial FDG Uptake (From Baseline) in the Most Diseased Segment | baseline and 24 weeks | Arterial FDG Uptake provides a measure of inflammation in the artery wall. TBR is target-to-background ratio (a measure of the ratio of the activity in the vessel wall divided by the blood background). A negative number for the change in TBR implies a reduction in activity over time. The most diseased segment is the approx 1-cm section of the vessel with the highest activity at baseline. The results are expressed as the change in the median value, of the TBR, from baseline to week 24 |
| Secondary | Change in Arterial FDG Uptake (From Baseline) in the Aorta | baseline and 24 weeks | Arterial FDG Uptake provides a measure of inflammation in the artery wall. TBR is target-to-background ratio (a measure of the ratio of the activity in the vessel wall divided by the blood background). A negative number for the change in TBR implies a reduction in activity over time. The entire ascending aorta is used for this analysis. The results are expressed as the change in the median value, of the TBR, from baseline to week 24 |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Arterial FDG Uptake (From Baseline) in the Most Diseased Segment | baseline and 24 weeks | TBR | MEDIAN | |
| SECONDARY | Change in Arterial FDG Uptake (From Baseline) in the Aorta | baseline and 24 weeks | TBR | MEDIAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Arterial FDG Uptake (From Baseline) in the Most Diseased Segment | Low Dose Methotrexate | -0.126 | Inter-Quartile Range -0.41 to 0.258 | TBR | |
| Change in Arterial FDG Uptake (From Baseline) in the Most Diseased Segment | Placebo | 0.026 | Inter-Quartile Range -0.176 to 0.438 | TBR | |
| Change in Arterial FDG Uptake (From Baseline) in the Aorta | Low Dose Methotrexate | -0.064 | Inter-Quartile Range -0.327 to 0.113 | TBR | |
| Change in Arterial FDG Uptake (From Baseline) in the Aorta | Placebo | 0.063 | Inter-Quartile Range -0.13 to 0.425 | TBR |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Low Dose Methotrexate | 13 | |
| Overall Study | STARTED | Placebo | 22 | |
| Overall Study | COMPLETED | Low Dose Methotrexate | 12 | |
| Overall Study | COMPLETED | Placebo | 16 | |
| Overall Study | NOT COMPLETED | Low Dose Methotrexate | 1 | |
| Overall Study | NOT COMPLETED | Placebo | 6 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Low Dose Methotrexate | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Low Dose Methotrexate | 0 | 12 |
| Total, other adverse events | Placebo | 0 | 16 |
| Total, serious adverse events | Low Dose Methotrexate | 0 | 12 |
| Total, serious adverse events | Placebo | 0 | 16 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Low Dose Methotrexate vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02312219
GET https://conductscience.org/api/trials/v1/NCT02312219/registered